Filing Details

Accession Number:
0001437749-24-023533
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-26 10:50:20
Reporting Period:
2024-07-24
Accepted Time:
2024-07-26 10:50:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
907654 Arca Biopharma Inc. ABIO In Vitro & In Vivo Diagnostic Substances (2835) 363855489
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1274173 Plc Group Henderson Janus 201 Bishopgate
London X0 EC2M 3AE
No No Yes No
2030299 Ltd Fund Master Innovation Biotech Henderson Janus 201 Bishopgate
London X0 EC2M 3AE
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-07-24 165,000 $3.20 2,056,312 No 4 P Indirect By Fund
Common Stock Acquisiton 2024-07-24 17,800 $3.18 2,074,112 No 4 P Indirect By Fund
Common Stock Acquisiton 2024-07-24 7,056 $3.16 2,081,168 No 4 P Indirect By Fund
Common Stock Acquisiton 2024-07-25 30,227 $3.05 2,111,395 No 4 P Indirect By Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Fund
No 4 P Indirect By Fund
No 4 P Indirect By Fund
No 4 P Indirect By Fund
Footnotes
  1. The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.